Alira Health

Alira Health Announces the Spin-Off of Product Development Laboratory

Lab Will Continue to Innovate in Wound Care and Chronic Inflammatory Diseases as a Separate Company, ProDevLabs

Framingham, Mass. – Alira Health, a global healthcare advisory, clinical research and technology company, announces the spin-off of ProDevLabs, a new company led by Dr. Mitchell Sanders, PhD, a former Alira Health executive.

 

News
Published on:
May 2, 2023
Dr. Sanders is a visionary scientist who launched this product development lab at Alira Health in 2015. It’s been a pleasure working with Mitch and nurturing the growth of the lab to become a successful business.
Gabriele Brambilla CEO

ProDevLabs will continue its groundbreaking work as a product development lab focused on chronic inflammatory diseases, including wound care, cancer, infections/biofilms, and neuropathologies such as traumatic brain injury, Alzheimer’s, and Parkinson’s.

“Dr. Sanders is a visionary scientist who launched this product development lab at Alira Health in 2015,” said Gabriele Brambilla, CEO and Co-Founder of Alira Health. “It’s been a pleasure working with Mitch and nurturing the growth of the lab to become a successful business.”

“ProDevLabs will continue its growth trajectory as a best-in-class CRO,” said Dr. Sanders. “We plan to add new talent and resources to accommodate our clients’ needs. I am grateful to Alira Health for the opportunity to grow these services over the last eight years and look forward to maintaining our close relationship with Alira Health.”

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

Related news

Articles March 27, 2025
Tangible Ways Patient Insights Accelerate Access and Product Launch
This article explores how leveraging patient insights can help companies overcome market access barriers and improve their chances of success.
Patient Centricity Patient Engagement Patient-Enabled Innovation Product Development
Events March 12, 2025
Healthtech Accelerations Summit 2025
Meet our experts to discover how we support companies bring innovation to patients by structuring drug development into clear, achievable inflection points.
Biotech Drug Development EU Healthcare Technology
News December 17, 2024
Alira Health Secures Up to $100M Growth Debt Facility from Symbiotic Capital to Propel Strategic Expansion and Patient-Enabled Innovation
This funding will drive Alira Health’s strategic growth, enhance its innovative technology platforms, and support solutions that empower patients and create value for life sciences companies.
Biopharma Life Sciences MedTech Patient-Enabled Innovation Strategic Expansion
Articles December 16, 2024
2024 Recap: Your Favorite Alira Health Publications
As we wrap up 2024, we’re sharing Alira Health's top ten most popular publications with you.
Life Sciences Patient Engagement
Articles November 12, 2024
Global Biosimilars Landscape in 2024: Trends, Challenges, and Opportunities
The introduction of biosimilars marks a significant evolution in healthcare, offering comparable therapeutic benefits at lower costs.
Biologics Biosimilars Drug Development
Reports October 23, 2024
2024 Global Biosimilars Report
Download for an assessment of trends in the global biosimilar market, with an emphasis on market and competitive dynamics in the US and Europe.
Biologics Biosimilars Drug Development
Uncategorized October 8, 2024
Critical Quality Attributes for Drug Products Preview
In this article, we explore the importance of Critical Quality Attributes in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
Biotech CDMO Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.